ProShare Advisors’s Eledon Pharmaceuticals ELDN Stock Holding History

ProShare Advisors’s Portfolio ELDN Stock Details ELDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$39.7K	Sell	10,086 -746	-7%	-$2.71K	﹤0.01%	1861
2026 Q1	$33.4K	Buy	10,832 +566	+6%	+$1.33K	﹤0.01%	1816
2025 Q4	$15.5K	Buy	+10,266	New	+$24.4K	﹤0.01%	2024
2025 Q3	–	Sell	-12,019	Closed	-$32.6K	–	2044
2025 Q2	$32.6K	Buy	+12,019	New	+$36.1K	﹤0.01%	2035
2016 Q4	–	Sell	-94	Closed	-$23K	–	1744
2016 Q3	$23K	Sell	94 -17	-15%	-$6.22K	﹤0.01%	1454
2016 Q2	$100K	Buy	111 +1	+0.9%	+$1.1K	﹤0.01%	1522
2016 Q1	$100K	Sell	110 -11	-9%	-$10.8K	﹤0.01%	1521
2015 Q4	$170K	Buy	+121	New	+$211K	﹤0.01%	1577

Other funds holding ELDN

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DCM

Defilade Capital Management Emeryville, California $747M AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

CCM

Catalio Capital Management New York $532M AUM 166.55% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Zimmer Partners New York $4.34B AUM 22.78% 1-Year Est. Return

ProShare Advisors's ELDN Position: Q2 2026 in Review

ProShare Advisors reduced its Eledon Pharmaceuticals (ELDN) stake by 6.9% in Q2 2026, selling an estimated $2.71K and leaving 10,086 shares worth $39.7K. The position accounts for ﹤0.01% of the portfolio, ranked #1861.

ProShare Advisors first reported a position in ELDN in Q4 2015 and has held it in 8 quarters since. The position peaked at $170K in Q4 2015. 160 funds tracked by Wall St. Rank hold ELDN as of Q2 2026.

ProShare Advisors held 10,086 shares of Eledon Pharmaceuticals worth $39.7K as of Q2 2026.
ProShare Advisors sold 746 Eledon Pharmaceuticals shares in Q2 2026, an estimated $2.71K.
Eledon Pharmaceuticals made up ﹤0.01% of ProShare Advisors's portfolio in Q2 2026, its #1861 holding.
ProShare Advisors first reported a position in Eledon Pharmaceuticals in Q4 2015 and has held it in 8 quarters since.
ProShare Advisors's Eledon Pharmaceuticals position peaked at $170K in Q4 2015.
160 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q2 2026.

Based on ProShare Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.